Previous 10 | Next 10 |
Altamira Therapeutics (NASDAQ:CYTO) announced positive outcomes from testing Bentrio for protection in human rhinovirus (or HRV) infection. Bentrio is a drug-free nasal spray developed and commercialized by the company's affiliate Altamira Medica for protection against airborne...
Testing further confirms Bentrio's broad protection against various types of airborne viruses Demonstrates significant reductions in viral load for preventive and mitigative treatment after 4 days vs. saline controls HAMILTON, BERMUDA / ACCESSWIRE / June 8, 2022 / Altamira Therap...
Altamira Therapeutics (NASDAQ:CYTO) said that the Ministry of Health of Indonesia approved its Bentrio nasal spray, designed to protect against airborne viruses and allergens. The company added that the product will be commercialized through a local affiliate of Wellesta Holdings, Singap...
HAMILTON, BERMUDA / ACCESSWIRE / May 31, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, announced today that Bentrio™ has been approved by the Ministry of Health of Indonesia and is, therefore...
Altamira Therapeutics (NASDAQ:CYTO) stock rose ~5% after the company said that the Philippines' Food and Drug Administration (FDA) approved its Bentrio nasal spray, designed to protect against airborne viruses and allergens. The company said the product will be commercialized through the...
HAMILTON, BERMUDA / ACCESSWIRE / May 23, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that Bentrio™ has been approved by the Philippines' Food and Drug Administration (FDA) a...
Company's drug-free nasal spray demonstrated a statistically significant reduction of nasal symptoms vs. untreated controls as well as good tolerability and safety HAMILTON, BERMUDA / ACCESSWIRE / May 20, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing t...
HAMILTON, BERMUDA / ACCESSWIRE / May 19, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO) , a company dedicated to developing therapeutics that address important unmet medical needs, today announced that it is scheduled to present virtually at the H.C. Wainwright Global Investment Conferen...
Highlights Company's progress to becoming a pure-play RNA business and tech strategy and penetrate the multi-billion TAM HAMILTON, BERMUDA / ACCESSWIRE / May 18, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet ...
Hamilton, Bermuda-based pharma company Altamira Therapeutics (NASDAQ:CYTO) announced on Thursday that the officials in North Macedonia approved its request to expand the COVAMID clinical study for Bentrio for patients with acute COVID-19 in the region. "Extending our study into North Macedoni...
News, Short Squeeze, Breakout and More Instantly...
Altamira Therapeutics Ltd. Company Name:
CYTO Stock Symbol:
NASDAQ Market:
Hamilton, Bermuda, May 01, 2024 (GLOBE NEWSWIRE) -- Continued expansion of IP portfolio related to RNA delivery Treatment of rheumatoid arthritis as one of the key therapeutic indications HAMILTON, BERMUDA / May 1, 2024 / Altamira Therapeutics Ltd. (“Altamira” or t...
Hamilton, Bermuda, April 24, 2024 (GLOBE NEWSWIRE) -- Detailed results from randomized controlled Bentrio® trial in seasonal allergic rhinitis published in Allergy journal Study met primary efficacy endpoint of improvement in nasal symptoms (p = 0.013) Corroborated ...
Hamilton, Bermuda, April 10, 2024 (GLOBE NEWSWIRE) -- Management to host conference call today, April 10, at 8.30 a.m. EDT RNA delivery business progressing with new collaborations, potential new applications Partnering of legacy assets underway as Company transitions to f...